Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

× No keyword cloud information.

6 in total

1. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America.

Authors: J G Bartlett; R F Breiman; L A Mandell; T M File
Journal: Clin Infect Dis Date: 1998-04 Impact factor: 9.079

2. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.

Authors: T M File; J Segreti; L Dunbar; R Player; R Kohler; R R Williams; C Kojak; A Rubin
Journal: Antimicrob Agents Chemother Date: 1997-09 Impact factor: 5.191

3. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.

Authors: P M Roblin; M R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 1998-01 Impact factor: 5.191

4. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.

Authors: S Block; J Hedrick; M R Hammerschlag; G H Cassell; J C Craft
Journal: Pediatr Infect Dis J Date: 1995-06 Impact factor: 2.129

5. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro.

Authors: S Dessus-Babus; C M Bébéar; A Charron; C Bébéar; B de Barbeyrac
Journal: Antimicrob Agents Chemother Date: 1998-10 Impact factor: 5.191

6. Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis.

Authors: P Léophonte; R J Baldwin; N Pluck
Journal: Eur J Clin Microbiol Infect Dis Date: 1998-06 Impact factor: 3.267

6 in total

5 in total

Review 1. Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors: Jens Boman; Margaret R Hammerschlag
Journal: Clin Microbiol Rev Date: 2002-01 Impact factor: 26.132

2. In Vitro Activity of Levonadifloxacin (WCK 771) against Chlamydia pneumoniae.

Authors: Stephan Kohlhoff; Natalia Huerta; Margaret R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 2019-07-25 Impact factor: 5.191

3. In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.

Authors: Sheila Malay; Patricia M Roblin; Tamara Reznik; Andrei Kutlin; Margaret R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 2002-02 Impact factor: 5.191

4. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.

Authors: Andrei Kutlin; Patricia M Roblin; Margaret R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 2002-02 Impact factor: 5.191

5. In vitro and in vivo activities of sitafloxacin against Chlamydia spp.

Authors: N Miyashita; Y Niki; T Matsushima
Journal: Antimicrob Agents Chemother Date: 2001-11 Impact factor: 5.191

5 in total